BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 25267460)

  • 21. Accuracy of 3 Tesla pelvic phased-array multiparametric MRI in diagnosing prostate cancer at repeat biopsy.
    Pepe P; Garufi A; Priolo G; Dibenedetto G; Salemi M; Pennisi M; Fraggetta F; Aragona F; Barbera M
    Arch Ital Urol Androl; 2014 Dec; 86(4):336-9. PubMed ID: 25641466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
    Kuru TH; Roethke MC; Seidenader J; Simpfendörfer T; Boxler S; Alammar K; Rieker P; Popeneciu VI; Roth W; Pahernik S; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2013 Oct; 190(4):1380-6. PubMed ID: 23608676
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective comparison of a fast 1.5-T biparametric with the 3.0-T multiparametric ESUR magnetic resonance imaging protocol as a triage test for men at risk of prostate cancer.
    Van Nieuwenhove S; Saussez TP; Thiry S; Trefois P; Annet L; Michoux N; Lecouvet F; Tombal B
    BJU Int; 2019 Mar; 123(3):411-420. PubMed ID: 30240059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Real-time elastography in the diagnosis of prostate cancer: personal experience].
    Romagnoli A; Autieri G; Centrella D; Gastaldi C; Pedaci G; Rivolta L; Pozzi E; Anghileri A; Cerabino M; Bianchi CM; Roggia A
    Urologia; 2010; 77(4):248-53. PubMed ID: 21234867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective study investigating the impact of multiparametric MRI in biopsy-naïve patients with clinically suspected prostate cancer: The PROKOMB study.
    Baur ADJ; Henkel T; Johannsen M; Speck T; Weißbach L; Hamm B; König F
    Contemp Clin Trials; 2017 May; 56():46-51. PubMed ID: 28279782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.
    van Leeuwen PJ; Hayen A; Thompson JE; Moses D; Shnier R; Böhm M; Abuodha M; Haynes AM; Ting F; Barentsz J; Roobol M; Vass J; Rasiah K; Delprado W; Stricker PD
    BJU Int; 2017 Dec; 120(6):774-781. PubMed ID: 28207981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of prostate cancer in patients with persistently elevated PSA and tumor-negative biopsy in ambulatory care: performance of MR imaging in a multi-reader environment.
    Scheidler J; Weöres I; Brinkschmidt C; Zeitler H; Panzer S; Scharf M; Heuck A; Siebels M
    Rofo; 2012 Feb; 184(2):130-5. PubMed ID: 22274854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
    Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J
    Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy.
    Komai Y; Numao N; Yoshida S; Matsuoka Y; Nakanishi Y; Ishii C; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    J Urol; 2013 Sep; 190(3):867-73. PubMed ID: 23542406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of classical transrectal prostate biopsy versus cognitive registration in rebiopsy.
    Barbas Bernardos G; Herranz Amo F; de Miguel Campos E; Luis Cardo A; Herranz Arriero A; Cancho Gil MJ; Caño Velasco J; Jara Rascón J; Mayor de Castro J; Hernández Fernández C
    Actas Urol Esp (Engl Ed); 2019 Jun; 43(5):228-233. PubMed ID: 30833102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
    Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
    NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
    Fütterer JJ; Briganti A; De Visschere P; Emberton M; Giannarini G; Kirkham A; Taneja SS; Thoeny H; Villeirs G; Villers A
    Eur Urol; 2015 Dec; 68(6):1045-53. PubMed ID: 25656808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
    Hambrock T; Somford DM; Hoeks C; Bouwense SA; Huisman H; Yakar D; van Oort IM; Witjes JA; Fütterer JJ; Barentsz JO
    J Urol; 2010 Feb; 183(2):520-7. PubMed ID: 20006859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiparametric MRI of the prostate with three functional techniques in patients with PSA elevation before initial TRUS-guided biopsy.
    Hauth E; Hohmuth H; Cozub-Poetica C; Bernand S; Beer M; Jaeger H
    Br J Radiol; 2015 Oct; 88(1054):20150422. PubMed ID: 26268144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
    Teixeira Anacleto S; Neves Alberto J; Carvalho Dias E; Sousa Passos P; Cerqueira Alves M
    Arch Ital Urol Androl; 2022 Mar; 94(1):32-36. PubMed ID: 35352522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
    Salami SS; Vira MA; Turkbey B; Fakhoury M; Yaskiv O; Villani R; Ben-Levi E; Rastinehad AR
    Cancer; 2014 Sep; 120(18):2876-82. PubMed ID: 24917122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
    De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
    Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of mpMRI and PSA density in patients with an initial negative prostatic biopsy.
    Kotb AF; Spaner S; Crump T; Hyndman ME
    World J Urol; 2018 Dec; 36(12):2021-2025. PubMed ID: 29808301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The additive value of mpMRI on prostate cancer detection: Comparison between patients with and without a suspicious digital rectal examination (DRE).
    Omri N; Alex S; Jacob B; Ofer N
    Urol Oncol; 2021 Oct; 39(10):728.e7-728.e11. PubMed ID: 33454199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.